M&A Deal Summary

Gilead Sciences Acquires Kite Pharma

On August 28, 2017, Gilead Sciences acquired life science company Kite Pharma for 11.9B USD

Acquisition Highlights
  • This is Gilead Sciences’ 15th transaction in the Life Science sector.
  • This is Gilead Sciences’ 2nd largest (disclosed) transaction.
  • This is Gilead Sciences’ 11th transaction in the United States.
  • This is Gilead Sciences’ 3rd transaction in California.

M&A Deal Summary
Date 2017-08-28
Target Kite Pharma
Sector Life Science
Buyer(s) Gilead Sciences
Deal Type Add-on Acquisition
Deal Value 11.9B USD
Advisor(s) Centerview Partners
Jefferies
Cowen Group, Inc. (Financial)
Sullivan & Cromwell (Legal)

Target

Kite Pharma

Santa Monica, California, United States
website
Kite Pharma's corporate headquarters in Santa Monica, California.
Kite Pharma's corporate headquarters in Santa Monica, California.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. Kite Pharma was formed in 2009 and is based in Santa Monica, California.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Gilead Sciences

Foster City, California, United States

website

Category Company
Founded 1987
Sector Life Science
Employees11,000
Revenue 27.3B USD (2022)
DESCRIPTION
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.

DEAL STATS #
Overall 16 of 24
Sector (Life Science) 15 of 23
Type (Add-on Acquisition) 13 of 20
State (California) 3 of 8
Country (United States) 11 of 17
Year (2017) 1 of 1
Size (of disclosed) 2 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-16 Gilead Sciences - GS-6637

Foster City, California, United States

Gilead Sciences, Inc. - GS-6637 is a Phase-2 ready compound that utilizes a novel pathway for the treatment of addiction. GS-6637 is highly selective ALDH2 inhibitor that modifies dopaminergic tone by preventing pathophysiologic dopamine surges and associated craving without changes to basal dopamine.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-03-02 Forty Seven

Menlo Park, California, United States

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Forty Seven’s lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages.

Buy $4.9B
Mergr

Product

Company

Legal